Patent classifications
A61K51/06
HYDROGEL AND METHOD FOR PREPARING THE SAME
The present disclosure provides a hydrogel having excellent drug delivery ability and having antibacterial properties as well as pH-dependent, biocompatible and biodegradable properties, and a method for preparing the same. The hydrogel including radiated chitosan, a natural gelling polymer, a hydrophilic synthetic polymer and (3-mercaptopropyl)trimethoxysilane (MPTMS), and the method for preparing the same are provided.
HYDROGEL AND METHOD FOR PREPARING THE SAME
The present disclosure provides a hydrogel having excellent drug delivery ability and having antibacterial properties as well as pH-dependent, biocompatible and biodegradable properties, and a method for preparing the same. The hydrogel including radiated chitosan, a natural gelling polymer, a hydrophilic synthetic polymer and (3-mercaptopropyl)trimethoxysilane (MPTMS), and the method for preparing the same are provided.
COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME
Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions.
BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS
The present disclosure relates to the delivery of multiple copies of a payload molecule such as an active agent or a chelating agent capable of capturing an active agent, using as a carrier for their delivery a biocompatible copolymer comprising side chain-linked amino acids functionalized at their alpha-amino group by a reactive azide moiety by means of which the payload molecules are coupled to the copolymer. The copolymer is typically further functionalized to contain a single copy of a cell type- or tissue type-specific targeting moiety.
Polymer coatings for brachytherapy devices
Described embodiments include an apparatus (20, 21), which includes a support (22), including an outer surface (24) and configured for insertion into a body of a subject. The apparatus further includes multiple atoms (26) of a radionuclide, which radioactively decays to produce a daughter radionuclide, coupled to the outer surface, and a layer (28, 33) of a polymer, which is permeable to the daughter radionuclide, that covers the atoms. Other embodiments are also described.
Polymer coatings for brachytherapy devices
Described embodiments include an apparatus (20, 21), which includes a support (22), including an outer surface (24) and configured for insertion into a body of a subject. The apparatus further includes multiple atoms (26) of a radionuclide, which radioactively decays to produce a daughter radionuclide, coupled to the outer surface, and a layer (28, 33) of a polymer, which is permeable to the daughter radionuclide, that covers the atoms. Other embodiments are also described.
METHOD FOR PREPARING A RADIONUCLIDE-COATED MICROSPHERE
A process for delivering a radionuclide material is provided in which the radionuclide, such as holmium oxide, is coated on a glass microsphere. A coating, preferably a dipodal polysiloxane, is applied to the microsphere, which coating has an affinity for the radionuclide. The radionuclide material is milled to decrease agglomerations and then deposited onto the coating to form a radionuclide-coated microsphere. The radionuclide-coated microsphere provides metered delivery of the radionuclide material.
POLYMERIC RADIATION-SOURCES
A polymeric radiation-source with customized geometries to maximize receipt of radiation into treatment areas that is formed from either radioisotopes molecularly bonded to a polymer or radioisotopes encased within a polymer.
TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula
##STR00001##
or a pharmaceutically acceptable salt thereof.
TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
- Niels BÖHNKE ,
- Sabine ZITZMANN-KOLBE ,
- Stefanie Hammer ,
- Sven Wittrock ,
- Donald Bierer ,
- Thorsten POETHKO ,
- Hans Briem ,
- Holger Magnus STEUBER ,
- Martina SCHÄFER ,
- Robin Michael MEIER ,
- Arif CELIK ,
- Cornelia Preusse ,
- Antje Rottmann ,
- Nicolas Werbeck ,
- Alexander KRISTIAN ,
- Bård INDREVOLL ,
- Alan Cuthbertson ,
- Alex PAPPLE
A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.
##STR00001##